Clinical Research Directory

Inclusion Criteria: 1. Cytologically or histologically confirmed newly diagnosed locally advanced, unresectable or metastatic pancreatic adenocarcinoma (excluding other pancreatic malignancies such as acinar cell carcinomas or neuroendocrine cell neoplasms, etc.). 2. Eligible for reassessment following 2 months of front-line chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel): Patient must have experienced a response of SD, PR, or CR per RECIST v1.1 after 2 months of front-line chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel). 3. ≥18 years of age prior to administration of MT-601. 4. Measurable or evaluable disease per RECIST v1.1 at the time of screening. 5. Must have sufficient leukapheresis material to manufacture autologous MT601. 6. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. 7. Life expectancy ≥12 weeks. 8. Pulse oximetry of \>90% on room air in patients with previous radiation therapy. 9. Adequate organ function, as defined below: * Absolute neutrophil count (ANC) ≥1.5 × 109/L * Platelets ≥75 × 109/L * Hemoglobin ≥9 g/dL (can be transfused) * International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × upper limit of normal (ULN) (unless patient receiving stable dose of anticoagulant therapy as long as PT or INR in therapeutic range of intended anticoagulant) * Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) PTT or aPTT ≤ 5 seconds above ULN (unless patient receiving stable dose of anticoagulant therapy "a" as long as PT or INR in therapeutic range of intended anticoagulant) * Total bilirubin ≤2 × ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN OR ≤5 × ULN if liver has tumor involvement * Serum creatinine OR calculated (as per institutional standards) creatinine clearance ≤2 × ULN OR measured or calculated ≥50 mL/min for patients "a" If receiving anticoagulation, the patient must have no active bleeding within 14 days prior to baseline assessment. 10. Sexually active patients must be willing to utilize one of the highly effective birth control methods or practice complete abstinence between initiation of screening for MT-601 infusion and 6 months after the last MT-601 infusion. Male patients who are sexually active must agree to use a condom during this period. 11. Disease imaging prior to administration of front-line chemotherapy and reimaging prior to administration of MT-601. Exclusion Criteria: * N/A